Research graph
References from Early tumor-informed circulating tumor DNA (ctDNA) dynamics correlate with response to first-line advanced NSCLC treated with pembrolizumab ± chemotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN
10.1016/j.canep.2024.102693 · 2024 · External reference
Survival of patients with lung adenocarcinoma diagnosed in 2000, 2010, and 2020
10.1056/evidoa2400443 · 2025 · External reference
The blockade of immune checkpoints in cancer immunotherapy
10.1038/nrc3239 · 2012 · External reference
Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
10.3389/fonc.2022.962947 · 2022 · External reference
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
10.1016/j.ejca.2008.10.026 · 2009 · External reference
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
10.1158/1078-0432.ccr-09-1624 · 2009 · External reference
Circulating mutant DNA to assess tumor dynamics
10.1038/nm.1789 · 2008 · External reference
The role of circulating tumor DNA in lung cancer: mutational analysis, diagnosis, and surveillance now and into the future
10.1007/s11864-019-0653-2 · 2019 · External reference
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
10.1136/jitc-2025-012454 · 2025 · External reference
Early assessment of lung cancer immunotherapy response via circulating tumor DNA
10.1158/1078-0432.ccr-17-1341 · 2018 · External reference
Early plasma circulating tumor DNA (ctDNA) changes to predict response to first-line pembrolizumab +/- chemotherapy in non-small cell lung cancer (NSCLC)
10.1200/jco.2020.38.15_suppl.3518 · 2020 · External reference
Identifying key circulating tumor DNA parameters for predicting clinical outcomes in metastatic non-squamous non-small cell lung cancer after first-line chemoimmunotherapy
10.1038/s41467-024-51316-7 · 2024 · External reference
Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)
10.1016/j.annonc.2023.12.007 · 2024 · External reference
Convergence of precision oncology and liquid biopsy in non-small cell lung cancer
10.1016/j.hoc.2023.02.005 · 2023 · External reference
Analysis of plasma cell-free DNA by ultra–deep sequencing in patients with stages I to III colorectal cancer
2019 · External reference
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling
10.1158/2159-8290.cd-17-0716 · 2017 · External reference
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
10.1038/s41591-023-02598-9 · 2023 · External reference
Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non–small cell lung cancer
10.1158/1078-0432.ccr-23-1578 · 2023 · External reference
Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis
10.1093/oncolo/oyae344 · 2025 · External reference
